Stockscreener 앱 받기
2.90
3.01%
-0.09
전일 마감가:
$2.99
열려 있는:
$2.92
하루 거래량:
52,210
Relative Volume:
0.02
시가총액:
$7.86M
수익:
$556.00K
순이익/손실:
$-5.28M
주가수익비율:
-1.3551
EPS:
-2.14
순현금흐름:
$-6.23M
1주 성능:
-0.68%
1개월 성능:
-9.09%
6개월 성능:
-12.39%
1년 성능:
-18.88%
1일 변동 폭
$2.85
$3.0899
1주일 범위
$2.80
$3.1992
52주 변동 폭
$1.27
$9.4699
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
명칭
Cyclerion Therapeutics Inc
전화
617-621-7722
주소
301 BINNEY STREET, CAMBRIDGE, MA
CYCN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
2.90 | 7.86M | 556.00K | -5.28M | -6.23M | -2.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-20 | 개시 | Truist | Buy |
| 2021-09-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-03 | 개시 | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc 주식(CYCN)의 최신 뉴스
Cyclerion Therapeutics (NASDAQ:CYCN) Shares Up 3.5% – Time to Buy? - Defense World
Looking Into Cyclerion Therapeutics's Recent Short Interest - Benzinga
Extended Session Gains Propel Cyclerion (CYCN) Amid Revenue Progress - Stocks Telegraph
Cyclerion Therapeutics (NASDAQ: CYCN) Amends License Agreement with Akebia Therapeutics and Generates Revenues for GrowthOn December 17, 2024, Cyclerion Therapeutics, Inc. filed an 8-K SEC Filing which detailed significant developments in its b - Defense World
Cyclerion advances growth strategy with new agreements - Investing.com
Cyclerion Therapeutics Secures Funding and Expands CNS Focus - TipRanks
Cyclerion advances growth strategy with new agreements By Investing.com - Investing.com UK
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth - GlobeNewswire
Cyclerion Strikes $560M Milestone Deal with Akebia, Completes Portfolio Monetization Strategy - StockTitan
Head to Head Survey: Cyclerion Therapeutics (NASDAQ:CYCN) vs. scPharmaceuticals (NASDAQ:SCPH) - Defense World
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update - Defense World
3 US Penny Stocks With Market Caps Under $100M - Simply Wall St
Cyclerion stock hits 52-week high at $5.25 amid market fluctuations - Investing.com Canada
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69% - Investing.com
Stock market news: Cyclerion Therapeutics +280.50%, Cross Country Healthcare +62.01% among top gainers during mid day trading - Business Upturn
Stock market news: Relmada Therapeutics plunged by 75.54% while Cyclerion Therapeutics surged by 280.12% during mid day trading - Business Upturn
Stock market today: Cyclerion Therapeutics +343.79%, Cross Country Healthcare +63.04% among top gainers in early trading - Business Upturn
Stock market today: Relmada Therapeutics declined by 74.74% while Cyclerion Therapeutics saw surge of 392.22% in early trading - Business Upturn
Cyclerion stock hits 52-week high at $5.25 amid market fluctuations By Investing.com - Investing.com South Africa
Why Nutanix Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket - Benzinga
CYCN (Cyclerion Therapeutics) 3-Year EBITDA Growth Rate : 57.30% (As of Sep. 2024) - GuruFocus.com
CYCN (Cyclerion Therapeutics) GF Value Rank : 5 (As of Nov. 25, 2024) - GuruFocus.com
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cyclerion stock hits 52-week low at $1.55 amid market challenges - Investing.com Canada
Cyclerion stock hits 52-week low at $1.55 amid market challenges By Investing.com - Investing.com South Africa
Cyclerion Therapeutics Inc (CYCN) Quarterly 10-Q Report - Quartzy
Cyclerion Therapeutics stock hits 52-week low at $1.75 By Investing.com - Investing.com South Africa
Cyclerion Therapeutics stock hits 52-week low at $1.75 - Investing.com India
Where Are They Now? Ironwood Pharmaceuticals - Life Science Leader Magazine
Vascular Dementia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Charsire Biotech Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP - Barchart
cyclerion therapeutics, inc. Earnings dates - RTTNews
Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 8.1% - Defense World
Analyzing Cyclerion Therapeutics (NASDAQ:CYCN) and Seelos Therapeutics (NASDAQ:SEEL) - Defense World
Cyclerion appoints Regina Graul as CEO and President - Investing.com
Cyclerion Therapeutics Promotes Regina Graul, Ph.D., to Chief Executive Officer - citybiz
Regina Graul, Ph.D., Promoted to Chief Executive Officer - StreetInsider.com
Short Interest in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Expands By 10.9% - Defense World
Cyclerion Therapeutics - BioSpace
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer - Marketscreener.com
Cyclerion Appoints Regina Graul, Ph.D., as President - citybiz
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - GlobeNewswire
Cyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With Losses - Yahoo Finance
Cyclerion in Talks on Buyout Proposal for Drug Assets; CEO Offers to Make Equity Investment - Marketscreener.com
Rapport Therapeutics Appoints Chief Operating Officer and Scientific Advisory Board Member - Business Wire
Tisento Therapeutics Raises $81M in Series A - citybiz
Tisento Therapeutics Raises $81M in Series A Funding - FinSMEs
Bio Startup Tisento Launches With $81M and a Brain-Penetrating Drug in the Clinic - MedCity News
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Cyclerion Announces Reverse Stock Split - Yahoo Finance
Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors - Yahoo Finance
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 - GlobeNewswire
Cyclerion Therapeutics Inc (CYCN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):